healthcare
Claremont Creek Ventures portfolio company Gene Security Network (GSN) achieved a technical breakthrough that even Dear Abby can crow about. Never before, have scientists and clinicians been about to measure fetal DNA in a pregnant woman’s blood with enough accuracy to determine paternity or relevant information about the baby in utero — until now. If […]
Read More
Successful venture capital investing in molecular diagnostics requires proper commercialization of innovation. But how does this innovation get brought to market? The panel will explore the challenges of commercialization in a still-difficult business environment. These challenges include the cost-efficient development of technology that is truly disruptive yet cost-competitive. Panelists will discuss how to best determine […]
Read MoreI will be moderating a panel, Venture Capitalists’ Best Practices on Commercializing Innovation at the Molecular Diagnostics World Congress on September 29, 2011 at the South San Francisco Conference Center. Here’s the panel topic summary, hope to see you there. Successful venture capital investing in molecular diagnostics requires proper commercialization of innovation. But how does this innovation get […]
Read MoreJuly 1, 2011 source: Genetic Engineering & Biotechnology News by Brad Webb Rapid Transition from Laboratory Discoveries to Commercialization Is Transforming Healthcare It’s been less than a decade since a full human genome was sequenced, but already there is talk that the promise of genomics-inspired personal medicine is not being realized. I couldn’t disagree more. […]
Read MoreI was chatting recently with Venture Capital Journal’s Mark Boslet about a story concerning corporate venture capital investing and realized that Claremont Creek Ventures is among those VC firms witnessing first-hand heightened interest among corporations investing in venture-backed startups. We’re seeing activity, in particular, in healthcare and in clean technology, and it’s a good thing. […]
Read MoreMay 11, 2011 source: Wall Street Journal Health Blog Public Education and Gene Testing to Improve Medication Adherence There are tons of reasons why people don’t take the medications they’ve been prescribed, including side effects, cost and complicated drug regimens. A couple of different approaches to improving adherence are in the news today. The first […]
Read MoreMeet our team
Claremont Creek Ventures was founded in 2005 by Nat Goldhaber, John Steuart and Randy Hawks to pursue early stage investing in exceptional technology startups.
NAT GOLDHABER
Nat Goldhaber is a co-founder of Claremont Creek Ventures.
BRAD WEBB
Brad is focused on the role of genomics and biomarker data analytics in driving the next generation of diagnostics and drug development.
RANDY HAWKS
Randy Hawks is a co-founder of Claremont Creek Ventures.